Welcome to our dedicated page for Ironwood SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures, including Forms 10-K, 10-Q and 8-K. As a biotechnology company developing and commercializing therapies for gastrointestinal (GI) and rare diseases, Ironwood uses these filings to report on its financial condition, collaboration revenues from LINZESS® (linaclotide), progress of its apraglutide program, capital structure and risk factors.
In its annual reports on Form 10-K, Ironwood presents audited financial statements, management’s discussion and analysis of results, details on its GI and rare disease portfolio, and information about collaborations with partners such as AbbVie, Astellas and AstraZeneca. These filings also describe material weaknesses in internal control over financial reporting identified as of December 31, 2024, and the company’s efforts to address them.
Quarterly reports on Form 10-Q update investors on interim financial performance, including collaboration revenue tied to LINZESS U.S. net sales, research and development expenses related to apraglutide and other programs, restructuring charges, interest expense on convertible senior notes and revolving credit facilities, and non-GAAP measures such as adjusted EBITDA and non-GAAP net income or loss.
Current reports on Form 8-K provide timely disclosure of specific events. For Ironwood, 8-K filings in 2025 have covered topics such as Nasdaq notifications about bid price and filing timeliness, the company’s receipt of a Maximum Fair Price determination for LINZESS under the Inflation Reduction Act, changes in the independent registered public accounting firm, director resignations, and the public release of quarterly earnings press releases.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries designed to highlight key points from lengthy documents, such as shifts in financial guidance, updates on the apraglutide regulatory path, or changes in collaboration economics. Users can quickly identify information related to annual reports (10-K), quarterly reports (10-Q) and current reports (8-K), and can review disclosures that affect listing status, internal controls, and major GI and rare disease programs.
This page also helps investors monitor governance and compliance developments, including responses to Nasdaq listing rules and auditor changes, alongside the financial and operational data that shape the IRWD investment profile.
Ironwood Pharmaceuticals reported a sharp turnaround to profitability for the quarter ended March 31, 2026. Total revenues rose to $106.5 million from $41.1 million a year earlier, driven mainly by higher collaborative arrangements revenue from LINZESS in the U.S. and abroad.
Net income reached $40.8 million versus a net loss of $37.4 million in the prior-year quarter, with diluted earnings per share improving to $0.24 from a loss of $0.23. Operating income was $72.6 million compared with a loss of $29.1 million, reflecting higher revenue and lower research and development, selling, general and administrative, and restructuring costs.
Ironwood ended the quarter with $220.5 million in cash and cash equivalents. Liabilities included a $200.0 million tranche of 1.50% convertible senior notes due 2026 and $385.0 million outstanding under a revolving credit facility, contributing to a stockholders’ deficit of $217.1 million. The company continues to focus on LINZESS commercialization and advancing apraglutide through late-stage clinical development for short bowel syndrome with intestinal failure.
Ironwood Pharmaceuticals reported a strong turnaround in the first quarter of 2026, with total revenue of $106,506 (thousands), up from $41,143 (thousands) a year earlier. GAAP net income was $40,773 (thousands) versus a prior-year loss, and adjusted EBITDA reached $76,671 (thousands).
Growth was driven by LINZESS, with U.S. net sales of $272,525 (thousands), reflecting 97% year-over-year growth and 5% demand growth. The company maintained 2026 guidance, including U.S. LINZESS net sales of $1.125–$1.175 billion and adjusted EBITDA above $300 million.
Ironwood highlighted a planned confirmatory Phase 3 trial of apraglutide in short bowel syndrome and an FDA priority review of a LINZESS sNDA in younger pediatric patients, with a PDUFA date set for May 24. Management expects strong first-quarter revenue to support repayment of 2026 convertible notes at maturity in June.
Ironwood Pharmaceuticals is asking stockholders to approve four items at its virtual 2026 annual meeting on June 16, 2026 at 9:00 a.m. Eastern. Investors will vote on electing eight directors to one‑year terms, an advisory say‑on‑pay vote, and ratifying KPMG LLP as 2026 auditors.
A key proposal seeks to amend the Amended and Restated 2019 Equity Incentive Plan to add 10,000,000 more shares for equity awards. The proxy describes a largely independent board, detailed committee structure, director fees and stock‑based retainers, and a pay‑for‑performance program using cash bonuses and PSU/RSU equity tied to total stockholder return.
Bank of America Corporation reports beneficial ownership of 9,962,355 shares (Class A Common Stock) of Ironwood Pharmaceuticals, representing 6.1% of the class. The calculation references 163,058,316 shares outstanding as disclosed in the issuer's Form 10-K as of January 31, 2026. The filing (Schedule 13G/A) was submitted on behalf of Bank of America and certain wholly owned subsidiaries, including BofA Securities, Inc., Bank of America N.A., and Merrill Lynch International.
The Vanguard Group filed Amendment No. 5 to Schedule 13G/A reporting zero beneficial ownership of Ironwood Pharmaceuticals Inc. common stock. The filing states an internal realignment effective January 12, 2026 resulted in certain Vanguard subsidiaries reporting separately, and Vanguard no longer reports beneficial ownership of those subsidiary holdings.
The amendment identifies The Vanguard Group as the filer and shows 0 shares and 0% ownership; the form is signed by Ashley Grim on 03/27/2026.
Sarissa Capital Management LP and Alexander J. Denner filed Amendment No. 4 to their Schedule 13D for Ironwood Pharmaceuticals. The filing reports that Sarissa Capital may be deemed to beneficially own 9,188,635 shares, or approximately 5.6% of Ironwood’s Class A common stock.
Dr. Denner may be deemed to beneficially own 9,444,944 shares, representing about 5.8% of the outstanding shares, including those held through Sarissa-managed funds and those he holds directly as a director. On March 17, 2026, Sarissa Funds sold 6,725,000 shares at a weighted average price of $3.0501 per share and 5,800 shares at $3.3084 per share, for aggregate proceeds of $20,511,923 and $19,189, respectively.
On the same date, Dr. Denner was granted 4,451 shares in his capacity as a director of Ironwood. The filing states that, other than these transactions, no other transactions in the shares were effected by the reporting persons during the prior 60 days as of the afternoon of March 19, 2026.
IRONWOOD PHARMACEUTICALS INC director-related entities reported major share sales alongside a small equity grant. Investment vehicles advised by Sarissa Capital Management LP sold a total of 6,730,800 shares of Class A Common Stock on March 17, 2026 in open-market transactions at prices between $3.05 and $3.31 per share, leaving 9,188,635 shares held indirectly. Separately, Dr. Alexander J. Denner received a grant of 4,451 shares on March 13, 2026 under the company’s non-employee director compensation policy, bringing his directly held shares to 256,309. Footnotes state Sarissa Capital and its funds directly hold the sold and remaining indirect shares, with each party, including Dr. Denner, disclaiming beneficial ownership beyond their pecuniary interest.
Ironwood Pharmaceuticals Chief Legal Officer John Minardo received an equity grant of 136,612 shares of Class A Common Stock as a stock award. The shares were acquired at no cash cost to him as a grant or award, rather than an open-market purchase.
The award was granted in the form of restricted stock units as an annual performance award and will vest in four equal installments, with 25% of the underlying shares vesting on each approximate anniversary of the grant date. Following this grant, Minardo directly holds a total of 500,498 shares of Class A Common Stock.
Ironwood Pharmaceuticals reported that Chief Financial Officer Gregory S. Martini received an equity compensation grant of 136,612 shares of Class A Common Stock on March 10, 2026. The award is structured as restricted stock units granted as an annual performance award.
The award vests in four equal installments, with 25% of the shares vesting on each approximate anniversary of the grant date. Following this grant, Martini directly holds 297,213 shares of Class A Common Stock. This is a compensation-related acquisition, not an open-market purchase or sale.